Assembly Biosciences Inc (NASDAQ:ASMB) was the target of some unusual options trading on Monday. Stock traders acquired 2,876 call options on the stock. This is an increase of 2,317% compared to the average volume of 119 call options.
Assembly Biosciences stock opened at $14.78 on Tuesday. The stock has a market capitalization of $480.08 million, a price-to-earnings ratio of -3.71 and a beta of 1.75. Assembly Biosciences has a 12 month low of $13.13 and a 12 month high of $48.91.
Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.12). The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $3.69 million. Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. On average, equities research analysts anticipate that Assembly Biosciences will post -4.61 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc raised its position in Assembly Biosciences by 17.0% in the fourth quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 558 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Assembly Biosciences by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 5,524 shares during the last quarter. Two Sigma Investments LP bought a new position in Assembly Biosciences in the fourth quarter valued at about $336,000. Point72 Asset Management L.P. bought a new position in Assembly Biosciences in the third quarter valued at about $407,000. Finally, New York State Common Retirement Fund raised its position in Assembly Biosciences by 15.3% in the fourth quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 3,100 shares during the last quarter. Hedge funds and other institutional investors own 83.77% of the company’s stock.
Several analysts recently weighed in on ASMB shares. BidaskClub raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Thursday, February 21st. Finally, Chardan Capital reaffirmed a “hold” rating and issued a $30.00 price objective on shares of Assembly Biosciences in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Assembly Biosciences has an average rating of “Buy” and an average price target of $43.00.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
See Also: Call Option
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.